Alydia Health, Inc.

Organon appears to have had impressive wins in India for its women’s health portfolio as the Merck & Co., Inc. spin-out propels its business and disentangles itself from the parent entity in the co

Organon & Co. CEO Kevin Ali is the first to admit that the company faced a lot of skepticism when it spun out of Merck & Co., Inc. with three seemingly disparate sets of assets – established produc

Organon is progressing a multi-pronged strategy to accelerate growth in India, a market which presents some pressing statistics in terms of gaps in women’s health, a priority area for the Merck & Co

Merck & Co., Inc. spinout Organon is continuing its plan to build out a premier women’s health business via deal-making, announcing an $84m upfront acquisition of Forendo Pharma Oy and its invest